Patimah Ismail

Patimah Ismail


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2016 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
Mohammed ElluluMohammed Ellulu
Mohammed Ellulu
PIPatimah Ismail
Patimah Ismail
HKHuzwah Khaza'ai
Huzwah Khaza'ai
ARAsmah Rahmat
Asmah Rahmat
YAYehia Abed
Yehia Abed
FAFaisal Ali
Faisal Ali

1 October 2014 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Parham Jabbarzadeh KaboliParham Jabbarzadeh Kaboli
Parham Jabbarzadeh Kaboli
ARAsmah Rahmat
Asmah Rahmat
PIPatimah Ismail
Patimah Ismail
KLKing-Hwa Ling
King-Hwa Ling

1 July 2015 in Pharmacological Research
Verified
Journal Article
Closed access
Parham Jabbarzadeh KaboliParham Jabbarzadeh Kaboli
Parham Jabbarzadeh Kaboli
ARAsmah Rahmat
Asmah Rahmat
PIPatimah Ismail
Patimah Ismail
KLKing-Hwa Ling
King-Hwa Ling


12 June 2014 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
NRNurul Shazini Ramli
Nurul Shazini Ramli
Lindsay BrownLindsay Brown
Lindsay Brown
PIPatimah Ismail
Patimah Ismail
ARAsmah Rahmat
Asmah Rahmat
The fruit of Hylocereus polyrhizus, also known as red pitaya, and buah naga in Malay, is one of the tropical fruits of the cactus family, Cactaceae. Red pitaya has been shown to protect aorta from oxidative damage and improve lipid profiles in hypercholesterolemic rats probably due to phytochemicals content including phenolics and flavonoids. The aim of this study was to investigate the changes in cardiac stiffness, hepatic and renal function in high-carbohydrate, high-fat diet-induced obese rats following supplementation of red pitaya juice.

22 March 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Parham Jabbarzadeh KaboliParham Jabbarzadeh Kaboli
Parham Jabbarzadeh Kaboli
PIPatimah Ismail
Patimah Ismail
KLKing-Hwa Ling
King-Hwa Ling
RAF kinases are a family of enzymes in the MAP kinase pathway that contribute to the development of different types of cancer. BRAF is the most important member of RAF kinases. BRAF mutations have been detected in 7% of all cancers and 66% of melanomas; as such, the FDA has approved a few BRAF inhibitor drugs to date. However, BRAF can activate CRAF leading to resistance to BRAF inhibitors. Berberine (BBR) is an alkaloid that is widely distributed in different plant species. Several studies have been carried out on the anti-cancer effects of BBR but direct targets of BBR are unknown. In this study, interactions of BBR derivatives against BRAF and CRAF kinases were modeled and predicted using an in silico-based approach. To analyze and identify the residues important in BRAF docking, we modeled interactions of ATP, the universal substrate of BRAF, and found that Lys483 and Asp594 are the most important residues involved in both ATP and BBR binding [(The average score = -11.5 kcal/mol (ATP); Range of scores = -7.78 to -9.55 kcal/mol (BBR)]. In addition to these polar residues, Trp530 and Phe583 are also applicable to the molecular docking of BRAF. We also observed that Asp593 was excluded from the enzyme cavity, while Phe594 was included inside the cavity, making the enzyme inactive. Finally, three alternatives for BBR were identified with dual RAF inhibition effects [The best scores against BRAF = -11.62 kcal/mol (BBR-7), -10.64 kcal/mol (BBR-9), and -11.01 kcal/mol (BBR-10); the best scores against CRAF = -9.68 kcal/mol (BBR-7), -9.60 kcal/mol (BBR-9), and -9.20 kcal/mol (BBR-10)]. Direct effects of BBR derivatives against BRAF and CRAF kinases had not yet been reported previously, and, thus, for the first time, we report three cycloprotoberberines as lead compounds against RAF kinases.